Identification and characterization of a new chemotype of noncovalent SENP inhibitors.

Enzymes called SENPs catalyze both the maturation of small ubiquitin-like modifier (SUMO) precursors and removal of SUMO modifications, which regulate essential cellular functions such as cell cycle progression, DNA damage response, and intracellular trafficking. Some members, such as SENP1, are potential targets for developing cancer therapeutics. We searched for small molecule inhibitors of SENPs using in silico screening in conjunction with biochemical assays and identified a new chemotype of small molecule inhibitors that noncovalently inhibit SENPs. The inhibitors confer the noncompetitive inhibitory mechanism, as shown by nuclear magnetic resonance (NMR) and quantitative enzyme kinetic analysis. The NMR data also provided evidence for substrate-assisted inhibitor binding, which indicates the need for caution in using artificial substrates for compound screening, as the inhibitory effects could be significantly different from using the physiological substrates. This finding also suggests the possibility of designing inhibitors for this class of enzymes that are tuned for substrate-specificity.

[1]  Chris Carpenter.  Development of Small-Molecule CO2 Thickeners , 2014 .

[2]  F. Melchior,et al.  SUMO--nonclassical ubiquitin. , 2000, Annual review of cell and developmental biology.

[3]  T. A. Wilkinson,et al.  Identification of a SUMO-binding motif that recognizes SUMO-modified proteins. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[4]  Matthew P. Repasky,et al.  Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. , 2004, Journal of medicinal chemistry.

[5]  David Reverter,et al.  Structural basis for SENP2 protease interactions with SUMO precursors and conjugated substrates , 2006, Nature Structural &Molecular Biology.

[6]  R. Hay,et al.  Characterization of SENP7, a SUMO-2/3-specific isopeptidase. , 2009, The Biochemical journal.

[7]  Jinke Cheng,et al.  Role of desumoylation in the development of prostate cancer. , 2006, Neoplasia.

[8]  R. Hay,et al.  SUMO: a history of modification. , 2005, Molecular cell.

[9]  Jinke Cheng,et al.  SENP1 Induces Prostatic Intraepithelial Neoplasia through Multiple Mechanisms* , 2010, The Journal of Biological Chemistry.

[10]  S. Li,et al.  Insights into High Affinity Small Ubiquitin-like Modifier (SUMO) Recognition by SUMO-interacting Motifs (SIMs) Revealed by a Combination of NMR and Peptide Array Analysis* , 2011, The Journal of Biological Chemistry.

[11]  Jie Li,et al.  SUMO-specific protease 1 regulates the in vitro and in vivo growth of colon cancer cells with the upregulated expression of CDK inhibitors. , 2011, Cancer letters.

[12]  Ze'ev Ronai,et al.  Small Ubiquitin-related Modifier (SUMO)-specific Proteases , 2007, Journal of Biological Chemistry.

[13]  Ho Yin Chan,et al.  Crystal structure of the SENP1 mutant C603S-SUMO complex reveals the hydrolytic mechanism of SUMO-specific protease. , 2006, The Biochemical journal.

[14]  James H Naismith,et al.  SUMO protease SENP1 induces isomerization of the scissile peptide bond , 2006, Nature Structural &Molecular Biology.

[15]  E. Yeh,et al.  Heat shock and Cd2+ exposure regulate PML and Daxx release from ND10 by independent mechanisms that modify the induction of heat-shock proteins 70 and 25 differently , 2003, Journal of Cell Science.

[16]  Keith D Wilkinson,et al.  Distribution and paralogue specificity of mammalian deSUMOylating enzymes. , 2010, The Biochemical journal.

[17]  Jinke Cheng,et al.  SUMO-Specific Protease 1 Is Essential for Stabilization of HIF1α during Hypoxia , 2007, Cell.

[18]  Jinke Cheng,et al.  SUMO-specific protease 1 is essential for stabilization of HIF1alpha during hypoxia. , 2007, Cell.

[19]  G. Cagney,et al.  Small Ubiquitin-related Modifier (SUMO)-1 Promotes Glycolysis in Hypoxia* , 2010, The Journal of Biological Chemistry.

[20]  Wim J. N. Meester,et al.  Small‐Molecule Inhibitors and Probes for Ubiquitin‐ and Ubiquitin‐Like‐Specific Proteases , 2005, Chembiochem : a European journal of chemical biology.

[21]  Qingqing Meng,et al.  Design, synthesis, and biological evaluation of benzodiazepine-based SUMO-specific protease 1 inhibitors. , 2011, Bioorganic & medicinal chemistry letters.

[22]  E. Yeh,et al.  SENP 3 is responsible for HIF-1 transactivation under mild oxidative stress via p 300 de-SUMOylation , 2009 .

[23]  Matthew Bogyo,et al.  Development of small molecule inhibitors and probes of human SUMO deconjugating proteases. , 2011, Chemistry & biology.

[24]  Masaharu Uno,et al.  Discovery of 1-[4-(N-benzylamino)phenyl]-3-phenylurea derivatives as non-peptidic selective SUMO-sentrin specific protease (SENP)1 inhibitors. , 2012, Bioorganic & medicinal chemistry letters.

[25]  Mingyao Liu,et al.  Induction of SENP1 in Endothelial Cells Contributes to Hypoxia-driven VEGF Expression and Angiogenesis* , 2010, The Journal of Biological Chemistry.

[26]  J. Palvimo,et al.  SUMO-specific protease 1 (SENP1) reverses the hormone-augmented SUMOylation of androgen receptor and modulates gene responses in prostate cancer cells. , 2009, Molecular endocrinology.

[27]  James H Naismith,et al.  The structure of SENP1-SUMO-2 complex suggests a structural basis for discrimination between SUMO paralogues during processing. , 2006, The Biochemical journal.

[28]  B. Oh,et al.  DeSUMOylating isopeptidase: a second class of SUMO protease , 2012, EMBO reports.

[29]  E. Yeh,et al.  SUMOylation and De-SUMOylation: Wrestling with Life's Processes* , 2009, Journal of Biological Chemistry.

[30]  E. Yeh,et al.  SENP3 is responsible for HIF‐1 transactivation under mild oxidative stress via p300 de‐SUMOylation , 2009, The EMBO journal.